Cargando…
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
Histologic transformation from non-small cell to small cell lung cancer has been reported as a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung cancers. Whether small cell transformation occurs in other oncogene-driven lung cancers remains unknown. Here we analyze...
Autores principales: | Lin, Jessica J., Langenbucher, Adam, Gupta, Pranav, Yoda, Satoshi, Fetter, Isobel J., Rooney, Marguerite, Do, Andrew, Kem, Marina, Chang, Kylie Prutisto, Oh, Audris Y., Chin, Emily, Juric, Dejan, Corcoran, Ryan B., Dagogo-Jack, Ibiayi, Gainor, Justin F., Stone, James R., Lennerz, Jochen K., Lawrence, Michael S., Hata, Aaron N., Mino-Kenudson, Mari, Shaw, Alice T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400592/ https://www.ncbi.nlm.nih.gov/pubmed/32802958 http://dx.doi.org/10.1038/s41698-020-0127-9 |
Ejemplares similares
-
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020) -
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023) -
Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023) -
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022) -
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
por: Schneider, Jaime L., et al.
Publicado: (2022)